V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Receives registration of Valganciclovir powder for oral solution in Germany
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
General Medicine grows 5% and Vaccines 10% led by Shingrix
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
Subscribe To Our Newsletter & Stay Updated
